Study to Assess the Design of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures in Routine Clinical Practice

French Prospective Multicentre Non-Interventional Study to Assess the Design of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures in Routine Clinical Practice

The aim of the study is to explore how the individualized dosing regimen of REKOVELLE is used in routine clinical practice and to describe the effectiveness and safety of REKOVELLE under real-world conditions.

Inclusion Criteria:

• Females aged 18 years or older at enrolment
• Who are treated for IVF or ICSI treatment cycle using fresh or frozen ejaculated sperm from male partner or sperm donor
• Who are prescribed REKOVELLE for the first time and using the dosing algorithm to define the dose regimen: a previous cycle with REKOVELLE should not be allowed
• Who have been informed verbally and in writing about this study content and who do not object to their data being electronically processed.

Exclusion Criteria:

• Participating in an interventional clinical trial in which any treatment or follow-up is mandated
• Women with a contraindication for prescription of REKOVELLE treatment
• Oocyte donors
• Women undergoing ovarian stimulation for fertility preservation
• Women undergoing their third or fourth attempt of IVF or ICSI for the current parental project.
• Subject non-affiliated to French Social Security
• Women placed under judicial protection, guardianship, or supervision